Industry Insights
Increasing prevalence of type I and type II diabetes is expected to
drive the entire insulin market over the forecast period. Basically,
insulin is a peptide hormone secreted with the help of beta cells by
pancreas. The main function of insulin is to enable the absorption of
glucose from the blood in the body which provides energy to the body and
stabilize the level of blood glucose.
Continuous changing food habit of people coupled with changing life
style is anticipated to increase the rate of obsessed population which
is a factor triggering the market for diabetes. Furthermore, other
factors which support the growth of this market are increasing demand of
insulin analogs are rapid increase in geriatric population and growing
demand for minimal invasive and noninvasive treatment for diabetes.
Browse Detail Report With TOC @ http://www.hexaresearch.com/research-report/asia-pacific-insulin-industry
Increasing availability of safety pen needles and syringe in the
market is pushing the growth of this market owing to the effective
delivery of insulin. Both the public and private firms are taking active
participation for eradication and control of diabetes by investing huge
amount of fund for research and development. Increasing rate of
hypertension and destruction of beta cells are the prime reason for
occurrence of diabetes in one’s body.
The developing nations consists significant large potential market
for insulin which is needed to be served in order to maximize the
revenue and total market share. Continuous introduction of minimal
invasive diagnostic procedures has created a wide gap between the demand
and supply of insulin for the control of glucose level in blood.
Strong government support such as providing grants and subsidies to
insulin producing pharmacies is likely to trigger the demand for insulin
in coming five years. High production complexities and cost of
production are the restrains of insulin market. Rising target base
population and increasing level of awareness among people about
treatment of diabetes is expected to drive the market in future.
Request A Sample copy of This Report @ http://www.hexaresearch.com/sample/133
Product Insight
By product, the global insulin market is classified into rapid
acting, intermediate acting, short acting, long acting and pre-mixed
insulin. Among these, long acting insulin and immediate acting insulin
together contributed almost half of the entire insulin market share by
revenue, in 2013. Due to quick result of balancing blood sugar level,
the immediate acting insulin is anticipated to witness lucrative growth
over the forecast period. Apart from this, it has also widely accepted
by medical practitioners of hospitals and clinics.
Long acting insulin segment is also expected to grow with significant
rate owing to stabilize the level of blood glucose for few weeks. This
is a very effective way to control diabetes and has long lasting effect.
However, the dose of insulin is prescribed by doctors which depends on
various individuals such as consumption of alcohol, age of individual,
consumption of junk foods, personal insulin production rate and blood
glucose level.
Regional Insight
Asia Pacific region comprises of India, China, Australia, South
Korea, Brazil and Others developing nations. This region is anticipated
to witness the highest growth rate over the forecast period owing to
continuous increase in population leading to raise the overall targeted
market, rapidly increasing geriatric population base and rising
awareness about diabetes & its treatment. Continuous improvement in
healthcare infrastructure coupled with availability of sophisticated
technology is likely to push the growth of this market in next decade.
Competitors Insight
The market is oligopolistic in nature and there is strong barrier in
entry into this industry. Some of the major market players of the global
insulin market are Sanofi, Eli Lilly and Company, Novo Nordisk A/S,
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Biocon. The prices
of these companies product are entirely dependent in each other.
Table of Contents
Chapter 1. Executive Summary
1.1. Asia Pacific Insulin - Industry Summary and Critical Success Factors (CSFs)
Chapter 2. Asia Pacific Insulin Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Asia Pacific Insulin Market Dynamics
2.4. Key Opportunities Prioritized
2.5. Industry Analysis - Porter's
2.6. Asia Pacific Insulin - Company Market Share Analysis
2.7. Asia Pacific Insulin Market PESTEL Analysis, 2012
2.8. Asia Pacific Insulin – Pipeline Overview
Browse All Pharmaceuticals Industry Research Related Reports @http://www.hexaresearch.com/research-category/pharmaceuticals-industry/
Chapter 3. Asia Pacific Insulin Product Outlook, Volume (number of
units) and Value (USD Million) Estimates and Forecasts, 2012 - 2020
3.1. Rapid Acting Analog
3.2. Short Acting Insulin
3.3. Intermediate Acting Insulin
3.4. Long Acting Analog
3.5. Pre-Mixed
Chapter 4. Asia Pacific Insulin Segment (on the basis of source)
Outlook, Volume (number of units) and Value (USD Million) Estimates and
Forecasts, 2012 - 2020
4.1. Insulin Analogs
4.2. Human Recombinant Insulin
Chapter 5. Asia Pacific Insulin Application Outlook (USD Million) Estimates and Forecasts, 2012 - 2020
5.1. Type I and Other Diabetes
5.2. Type II Diabetes
Chapter 6. Insulin Regional Outlook, Volume (number of units) and Value (USD Million) Estimates and Forecasts, 2012 - 2020
6.1. India
6.2. China
6.3. Australia
6.4. New Zealand
6.5. South Korea
6.6. Taiwan
6.7. Philippines
6.8. Vietnam
6.9. Indonesia
6.10. Japan
6.11. Malaysia
6.12. Thailand
6.13. Rest of Asia Pacific
Chapter 7 Competitive Landscape
7.1 Novo Nordisk
7.2 Sanofi
7.3 Eli Lilly
7.4 Bristol-Myers Squibb
7.5 Novartis
7.6 Takeda Pharmaceuticals
7.7 Boehringer Ingelheim
7.8 Biocon
7.9 Dongbao Enterprise Group Co., Ltd.
7.10 Merck KGaA
7.11 Oramed Pharmaceuticals Inc.
7.12 Halozyme Therapeutics
7.13 Wanbang Biopharma
7.14 Xinbai Pharmaceutical
7.15 Gan & Lee Pharmaceutical
Browse Full Report @ http://www.hexaresearch.com/research-report/asia-pacific-insulin-industry
About Us:
Hexa Research is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
No comments:
Post a Comment